相关实验视频
Updated: May 31, 2025

07:37
Roux-en-Y Gastric Bypass Operation in Rats
Published on: June 11, 2012
23.5K
整形外科GLP-1激动剂:对美学结果的影响-两个病例报告
Federico Taraschi1, Marzia Salgarello2
1UOSD Chirurgia Plastica, Dipartimento per la Salute della Donna, del Bambino e di Sanità Pubblica - Fondazione Policlinico Universitario "Agostino Gemelli" IRCCS - Università Cattolica del "Sacro Cuore", Largo A. Gemelli 8, 00168, Rome, Italy. federico.taraschi595@gmail.com.
Aesthetic plastic surgery
|January 22, 2025
概括
用于减肥的葡萄糖类-1 (GLP-1) 受体激动剂可导致乳腺手术患者的伤口愈合延迟和脂肪缩. 这些发现表明需要仔细考虑GLP-1疗法在外科手术周围.
科学领域:
- 整形外科 整形外科 整形外科
- 内分泌学 在内分泌学.
- 药理学 药理学是指药理学的学科.
背景情况:
- 肥胖是一个全球性的健康问题,GLP-1受体激动剂提供有效的减肥解决方案.
- 这些药物可能会影响手术结果,特别是美容和重建手术中的伤口愈合和脂肪组织代谢.
- GLP-1激动剂越来越多地被处方,需要了解它们的经手术后影响.
研究的目的:
- 在使用GLP-1受体激活剂的患者中,记录了乳腺手术后两例受伤愈合受损和脂肪亡的病例.
- 提高临床医生的意识,了解与GLP-1激动剂使用和手术干预相关的潜在并发症.
- 为了解GLP-1对手术恢复的影响做出贡献.
主要方法:
- 观察了两名接受乳腺手术的患者 (用乳腺切除术和减少乳房整形术进行植入物更换).
- 这两名患者都在使用GLP-1激动剂 (liraglutide) 来控制体重.
- 一名患者在外科手术期间继续接受GLP-1治疗,而另一名患者在手术前7天停止服用药物.
主要成果:
- 两名患者均表现出延迟的伤口愈合,其特征是脂肪缩和二次愈合.
- 在这两种情况下都发生了伤口脱光,表明组织完整性受到损害.
- 尽管坚持标准的外科实践和术后护理,但愈合仍延长了.
结论:
- GLP-1诱导的体重减轻可能会对手术结果产生负面影响,包括伤口愈合.
- 观察到的延迟愈合和脂肪亡的并发症在GLP-1激动剂使用的背景下以前没有报告过.
- 需要进一步调查,以确定手术前最佳的GLP-1受体激动剂使用者进行手术的最佳手术前管理策略.
相关概念视频
Glucagon-like Receptor Agonists
294
Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
294
Dipeptidyl Peptidase 4 Inhibitors
165
Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a...
165

